criteria, to take part in the study. Those participants were then asked to refer to one or more colleagues for possible study enrolment. Once referred, the researchers then contacted potential participants to explain the study and assess their interest and eligibility. Interviews were conducted either on the telephone or face to face, at a mutually agreeable time and place from May to September 2019. Participants were eligible to take part if they were doctors, pharmacists or nurses, able to communicate in Arabic or English, and were aged ≥ 18 years. Interviews were conducted as needed until data saturation was achieved. Interviews were audio recorded, transcribed verbatim and analysed thematically using NVivo 10 software. Ethics approval was obtained from Imam Abdulrahman bin Faisal University.

Results Four overarching themes were identified in this study: 'types of shared medications' such as antibiotics, antihypertensives, cardiovascular, diabetic and cholesterol medicines; 'perceived benefits of sharing medicines' such as social support and saving time and money; 'negative experience of sharing medicines' such as personal and public health risks; 'reasons for medication sharing' such as lack of access to healthcare services or medicines, lack of medication knowledge, cost of medication, forgetfulness, medication non-adherence and altruistic reasons. Cultural influence, excessive amount of medication supply and lack of information about safe disposal were reasons that appeared to be specific to the Saudi culture.

Conclusion and relevance PMS was perceived as a behaviour with positive and negative outcomes. Interventions should be established to reduce PMS behaviour.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Beyene KA, Aspden TJ, Sheridan JL. A qualitative exploration of healthcare providers' perspectives on patients' non-recreational, prescription medicines sharing behaviours. *JPPR* 2018;**48**:158–166.

No conflict of interest.

5PSQ-079 IMMUNOTHERAPY IN METASTATIC MELANOMA: A MIRACLE OR POISON

¹H Attijou*, ²A Cheikh, ³MA El Wartiti, ¹Z Aliat, ¹I Bennani, ¹A Benomar, ⁴H Mefetah, ⁵M Bouatia. ¹Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Chis, Rabat, Morocco; ²Abulcasis University of Health Sciences, Pharmacy-Cheikh Zaid Hospital, Rabat, Morocco; ³Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Hospital Militaire D'instruction Mohamed V, Rabat, Morocco; ⁴Paediatrics Hospital, Pharmacy, Rabat, Morocco; ⁵Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Pharmacy-Paediatrics Hospital, Rabat, Morocco

10.1136/ejhp-pharm-2020-eahpconf.396

Background and importance Very significant therapeutic advances have been made with regard to immunotherapy in the treatment of metastatic melanoma. The use of monoclonal antibodies, particularly pembrolizumab, has shown encouraging results in terms of efficacy and survival in cancer patients, but some patients develop adverse reactions that can sometimes be fatal, or their management may require temporary or permanent interruption of treatment.

Aim and objectives We report the case of a patient who had immunological adverse reactions to pembrolizumab for metastatic melanoma.

Material and methods A 59-year-old patient was managed for lower limb melanoma in advanced locoregional evolutionary pursuit classified as T3b N3 M0. The absence of a BRAF mutation led to the introduction of immunotherapy with the

anti-PD1 antigen pembrolizumab. Two weeks after the second injection, an initial and transient increase in tumour size with the appearance of new small lesions was noticed, associated with intense fatigue, taste alteration with loss of appetite and constipation. After the third injection, a false progression of the tumour was noticed, requiring discontinuation of treatment. The patient was hospitalised for undernutrition with sudden weight loss, asthenia and general deterioration. Biological examinations revealed anaemia with severe undernutrition. Fatigue and altered condition did not allow the patient to undergo scheduled chemotherapy. The patient died within 3 months. The accountability study was carried out in accordance with the French method.

Results In this case, pembrolizumab was implicated with an imputability score of I5 B4, according to the French method.

Conclusion and relevance New immunotherapy approaches are characterised by a range of new toxicities that must be known, not only by medical oncologists and by all those involved in the management of oncology patients. Early detection of immunological toxicities and early application of available algorithms allow for complete resolution of symptoms in the majority of cases. However, if these symptoms are neglected, the development can lead to serious toxicities, including death of the patient.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Kennedy LB, Salama AKS. *Oncol Ther* 2019. <https://doi.org/10.1007/s40487-019-0096-8>
2. Levy D, Dhillon HM, Lomax A, et al. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. *Supportive Care in Cancer* 2018;1–8. 2/Cappelli L.

No conflict of interest.

5PSQ-080 ASSESSMENT OF DOSE PREPARATION PRACTICES FROM LIQUID ORAL FORMS BY MOTHERS OF CHILDREN HOSPITALISED IN OUR PAEDIATRIC DEPARTMENT

¹N Nchinech, ²H Attijou*, ³FZ Aglil, ³Y Kriouile, ³A Alaoui Mdaghri, ⁴Y Cherrah, ⁴S Serragui. ¹Mohammed V Military Training Hospital, Pharmacy, Rabat, Morocco; ²Paediatric Hospital-Chis-Rabat, Pharmacy, Rabat, Morocco; ³Paediatric Hospital-Chis-Rabat, Paediatrics 2, Rabat, Morocco; ⁴Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Pharmacology and Toxicology Department-Pharmacoeconomics and Pharmacoepidemiology Research Team, Rabat, Morocco

10.1136/ejhp-pharm-2020-eahpconf.397

Background and importance In our paediatric department, we welcome low income populations, it is the mothers who take care of the administration of oral treatments to their children. Because of the high rate of illiteracy among these mothers, this situation can lead to administration errors, particularly when it comes to oral presentations with a liquid administration device.

Aim and objectives To study the dose preparation errors of liquid oral forms by the mothers of hospitalised children.

Material and methods This prospective observational study was conducted in our paediatric department, between March and June 2019. During this period, interviews including a questionnaire in dialectal Arabic on how to use the liquid oral forms they administer to their children (administration schedule, preservation and interchangeability of graduated pipettes) were conducted. Subsequently, the preparation of drug intake of the two most prescribed liquid oral

presentations in the department was implemented: Amoxil (amoxicillin, measuring spoon) and Azimax (azithromycin, dose weight pipette).

Results A total of 77 mothers were included in the study. More than 75% (n=58) showed poor understanding of the intake method when we tried to have them repeat the dosing and administration schedule compared with the medical prescriptions they had. For 75.55% of the 45 mothers with a prescription containing Amoxil, the oral suspension, once reconstituted, was stored at room temperature when it required refrigeration (2–8°C). The response for the preservation of the two drugs after opening the vials was until expiration in 92.20% (n=71), while actually it is 7 days for Amoxil and 5 days for Azimax. Seventy-two interviewees thought that it was possible to exchange graduated pipettes. The Amoxil and Azimax reconstitutions were incorrect in 66.66% (30/45) and 81.25% (26/32) of cases, respectively, with the risk of overdose for Azimax (15/26) and underdosage for Amoxil (19/30). The preparation of the dose was incorrect in 60% of cases when using the dosing spoon with Amoxil and in 84.37% of cases when using the dosing pipette with Azimax.

Conclusion and relevance This study highlights the significant number of errors made by mothers during reconstitution and preparation of drugs, which requires the hospital pharmacist's involvement in educating families on the use of liquid oral forms.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

5PSQ-081 THE BENEFITS–RISKS BALANCE OF LEECH THERAPY IN ONE HOSPITAL: A RETROSPECTIVE STUDY

¹A Fillatre*, ²Q Floug, ¹K Hedli, ³R Sinna, ¹M Belhout, ²F Rousseau, ²N Lemaitre, ²F Hamdad. ¹Amiens-Picardie University Hospital, Department of Pharmacy, Amiens, France; ²Amiens-Picardie University Hospital, Department of Clinical Bacteriology, Amiens, France; ³Amiens-Picardie University Hospital, Department of Plastic Surgery, Amiens, France

10.1136/ejhp-pharm-2020-eahpconf.398

Background and importance Venous congestion in transplanted or re-implanted tissues remains a common and challenging complication in reconstructive surgery. Medicinal leeches have been increasingly used for salvage of compromised pedicle flaps and microvascular free tissue transfers. However, leech therapy is associated with a number of risks, including significant blood loss requiring transfusion and infections, as leeches maintain a symbiotic relationship with *Aeromonas* species, which are residents of their gut, in order to digest blood. This bacterial species appears to be the commonest cause of leech related infection and can result in extensive soft tissue infection.¹

Aim and objectives The aim of this study was to assess the benefits–risks of leech therapy. Indeed, in the era of increasing antibiotic resistance, leeches can be vectors of bacteria, harbouring resistance to major antibiotics. Thus we conducted a retrospective study on all patients who received leech therapy in our hospital, from 2010 to 2018.

Material and methods The purchase, maintenance and distribution of leeches in our hospital is centralised in the pharmacy from which the data on the numbers of leeches delivered to the clinical units, names of the patients and the number of leeches used per patient were obtained. We also performed a retrospective survey to assess the conditions of maintenance

and delivery of the leeches in the pharmacy and in the clinical units that used the most leeches.

Results Over 8 years, 42 patients were treated with an average of 34 leeches (5–126) over 2.5 days (1–12). The mean age of the patients was 48 years (34–93). There was a slight male predominance. Leeches were most commonly used by the plastic and reconstructive surgery unit. The success rate of leech therapy was 71.4%. However, 57% of patients developed anaemia, and 16.7% revealed *A. hydrophila* infections. All isolates were ticarcillin resistant, three were also fluoroquinolone resistant with one involving an extended spectrum β -lactamase producing one.

Conclusion and relevance In the era of increasing antibiotic resistance and before use of medicinal leeches, prior screening of resistance by a local pharmaceutical team seems logical and necessary.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Whitaker IS, et al. The efficacy of medicinal leeches in plastic and reconstructive surgery: a systematic review of 277 reported clinical cases. *Microsurgery* 2012;**32**:240e50.

No conflict of interest.

5PSQ-082 EVALUATING AN ELECTRONIC CLINICAL DECISION SUPPORT SYSTEM FOR DRUG–DRUG INTERACTIONS IN A LARGE ACUTE TEACHING HOSPITAL

N Sako*, B Carr, G Melanophy, M Henman, C Gavin. St James's Hospital-Dublin-Ire, Pha, Dublin, Ireland

10.1136/ejhp-pharm-2020-eahpconf.399

Background and importance Drug–drug interactions (DDIs) are common and can result in preventable harm. Clinical decision support systems (CDSS) embedded within electronic prescribing software (eg DDI alerting tools) may improve clinical decision making. Studies have shown that prescribers override up to 96% of CDSS alerts and have questioned the usefulness of alerting systems.

Aim and objectives The study's objective was to evaluate the characteristics and override rates of DDI alerts following a recent implementation of a hospital wide electronic prescribing systems incorporating a DDI CDSS which was set to flag 'major contraindicated' drug combinations only.

Material and methods A retrospective analysis of DDI alerts generated by Cerner electronic prescribing software over a 6 week period in a haematology–oncology inpatient cohort was completed. A parallel review of DDIs highlighted by clinical pharmacists in the same patient cohort was undertaken and the results were compared.

Results There were 310 electronic DDI alerts generated. Of these, 58 alerts were redundant as they referred to duplicates within the same prescribing episode (n=22) or were not triggered by current medications (n=36). The remaining 252 alerts involved 38 individual medicines and 44 medication pairs. Antiemetic medications accounted for over 50% of alerts and QTc interval prolongation was the most frequently alerted drug interaction adverse outcome. In 44 instances (17%) either the original prescription or the interacting medicine was changed by the prescriber following the DDI alert, reflecting an override rate of 83% (n=208).

A total of 37 DDI alerts were flagged by clinical pharmacists in the study. There were 42 individual medicines and 37 medication pairs involved. In 5 instances (14%), a change was